Profund Advisors
ZBIO icon

Profund Advisors’s Zenas BioPharma ZBIO Stock Holding History

Profund Advisors’s Portfolio ZBIO Stock Details ZBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$431K Sell
15,970
-2,868
-15% -$88.3K 0.01% 621
2026
Q2 		$478K Sell
18,838
-2,578
-12% -$51.2K 0.01% 573
2026
Q1 		$419K Buy
+21,416
New +$481K 0.02% 606

Other funds holding ZBIO

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Candriam SCA
Candriam SCA Strassen, Luxembourg, Luxembourg $22.5B AUM 50.38% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
ALPS Advisors
ALPS Advisors Denver, Colorado $21.8B AUM 17.58% 1-Year Est. Return
Citigroup
Citigroup New York $308B AUM 40.94% 1-Year Est. Return
iA Global Asset Management
iA Global Asset Management Quebec, Quebec, Canada $8.54B AUM 39.73% 1-Year Est. Return
Squarepoint
Squarepoint New York $90.8B AUM 26.98% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return
DA
DCF Advisers Greenwich, Connecticut $444M AUM 151.5% 1-Year Est. Return

Profund Advisors's ZBIO Position: Q3 2026 in Review

Profund Advisors reduced its Zenas BioPharma (ZBIO) stake by 15% in Q3 2026, selling an estimated $88.3K and leaving 15,970 shares worth $431K. The position accounts for 0.01% of the portfolio, ranked #621.

Profund Advisors first reported a position in ZBIO in Q1 2026 and has held it in 3 quarters since. The position peaked at $478K in Q2 2026. 48 funds tracked by Wall St. Rank hold ZBIO as of Q3 2026.

  • Profund Advisors held 15,970 shares of Zenas BioPharma worth $431K as of Q3 2026.
  • Profund Advisors sold 2,868 Zenas BioPharma shares in Q3 2026, an estimated $88.3K.
  • Zenas BioPharma made up 0.01% of Profund Advisors's portfolio in Q3 2026, its #621 holding.
  • Profund Advisors first reported a position in Zenas BioPharma in Q1 2026 and has held it in 3 quarters since.
  • Profund Advisors's Zenas BioPharma position peaked at $478K in Q2 2026.
  • 48 funds tracked by Wall St. Rank held Zenas BioPharma as of Q3 2026.

Based on Profund Advisors's 13F filing for Q3 2026, filed 29 Oct 2026.